Poliopolis: pushing boundaries of scientific innovations for disease eradication.

Although global polio eradication is within reach, sustained eradication of all polioviruses requires cessation of oral poliovirus vaccine use to mitigate against vaccine-derived poliovirus circulation and vaccine-associated paralytic poliomyelitis. The first step in this direction was the WHO-recommended global withdrawal of live attenuated type 2 Sabin poliovirus from routine immunisation in May 2016, with future use restricted to outbreak response, and handling controlled by strict containment provisions (GAPIII). This creates unique challenges for development and testing of novel type 2 poliovirus vaccines. We describe the creation of a novel purpose-built containment facility, Poliopolis, to study new monovalent OPV2 vaccine candidates in healthy adult volunteers, which may be a model for future endeavors in vaccine development for emergency use.

[1]  John O. Konz,et al.  The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study , 2019, The Lancet.

[2]  J. Vertefeuille,et al.  Progress Toward Polio Eradication — Worldwide, January 2017–March 2019 , 2019, MMWR. Morbidity and mortality weekly report.

[3]  G. Tallis,et al.  Notes from the Field: Circulating Vaccine-Derived Poliovirus Type 1 and Outbreak Response — Papua New Guinea, 2018 , 2019, MMWR. Morbidity and mortality weekly report.

[4]  Rui Fu,et al.  Assessing the Risk of Vaccine-derived Outbreaks After Reintroduction of Oral Poliovirus Vaccine in Postcessation Settings , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Modlin,et al.  Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Marisa C. Eisenberg,et al.  Epidemiology of the silent polio outbreak in Rahat, Israel, based on modeling of environmental surveillance data , 2018, Proceedings of the National Academy of Sciences.

[7]  Rob Lambkin-Williams,et al.  The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics , 2018, Respiratory Research.

[8]  Qi Chen,et al.  Vaccine-Derived Poliovirus Outbreaks and Events — Three Provinces, Democratic Republic of the Congo, 2017 , 2018, MMWR. Morbidity and mortality weekly report.

[9]  R. Sutter.  Unraveling the Mucosal Immunity of Inactivated Poliovirus Vaccine. , 2018, The Journal of infectious diseases.

[10]  S. Plotkin.  Vaccines for epidemic infections and the role of CEPI , 2017, Human vaccines & immunotherapeutics.

[11]  Hong‐Mei Liu,et al.  Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model , 2016, The Journal of infectious diseases.

[12]  G. Leroux-Roels,et al.  Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. , 2016, The Lancet. Infectious diseases.

[13]  H. Jafari,et al.  World Health Organization Guidelines for Containment of Poliovirus Following Type-Specific Polio Eradication - Worldwide, 2015. , 2015, MMWR. Morbidity and mortality weekly report.

[14]  Walter A Orenstein,et al.  Polio vaccination: past, present and future. , 2015, Future microbiology.

[15]  S. Arie.  Polio virus spreads from Syria to Iraq , 2014, BMJ : British Medical Journal.

[16]  M. Eichner,et al.  Polio emergence in Syria and Israel endangers Europe , 2013, The Lancet.

[17]  N. Grassly,et al.  Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge , 2012, PLoS pathogens.

[18]  G. Grard,et al.  Type 1 wild poliovirus and putative enterovirus 109 in an outbreak of acute flaccid paralysis in Congo, October-November 2010. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  M. Pallansch,et al.  Fractional doses of inactivated poliovirus vaccine in Oman. , 2010, The New England journal of medicine.

[20]  M. Birmingham,et al.  Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. , 2008, The Journal of infectious diseases.

[21]  M. Pallansch,et al.  A large vaccine-derived poliovirus outbreak on Madura Island--Indonesia, 2005. , 2008, The Journal of infectious diseases.

[22]  P. Roberts,et al.  Virus inactivation by protein denaturants used in affinity chromatography. , 2007, Biologicals : journal of the International Association of Biological Standardization.

[23]  Wenbo Xu,et al.  An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. , 2006, The Journal of infectious diseases.

[24]  T. Miyamura,et al.  A Sabin 3-Derived Poliovirus Recombinant Contained a Sequence Homologous with Indigenous Human Enterovirus Species C in the Viral Polymerase Coding Region , 2005, Journal of Virology.

[25]  Lilly Yuen,et al.  Circulation of Type 1 Vaccine-Derived Poliovirus in the Philippines in 2001 , 2004, Journal of Virology.

[26]  M. Pallansch,et al.  Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus , 2002, Science.

[27]  I. Onorato,et al.  Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. , 1991, The Journal of infectious diseases.